CONSULTANT HAEMATOLOGIST
Dr Ashish Panigrahi
MBBS FRACP
Dr Ashish Kumar Panigrahi is a Clinical Haematologist who has trained in Western Health, Royal Melbourne Hospital and Peter MacCallum Cancer Centre.
He has also served in regional Victoria at Bendigo Hospital as a Haematology Fellow. Dr Panigrahi has keen interests in both malignant and non-malignant haematology.
He has special interests in Multiple Myeloma, MPN disorders, lymphomas, MDS and elderly AML. Dr Panigrahi was involved as sub investigator in clinical trials at the Peter MacCallcum Cancer Centre. Dr Panigrahi endeavours to provide comprehensive patient centric care. His special research interests include Myeloproliferative Neoplasms in Younger patients.
Practice Interests
Dr Panigrahi has special interests in Multiple Myeloma, MPN disorders, lymphomas, MDS and elderly AML.
Dr Panigrahi believes in patient centric care. He strongly advocates good communication with patients and carers.
Practice Locations
Dr Panigrahi consults privately in his rooms located in Footscray and Sunbury
TeleHealth appointments are available.
Suite 6,
30 Eleanor Street
FOOTSCRAY VIC 3011
Tel: 1300 4 BLOOD / 1300 425 663
Fax: 03 8080 6482
Vineyard Medical Centre
2-6 Sussex Court
Sunbury VIC 3429
Tel: 1300 4 BLOOD / 1300 425 663
Fax: 03 8080 6482
Hospital Accreditation
Extended Profile
Dr Ashish Kumar Panigrahi
– Key Research, Journal & Book Publications, Presentations &/or Awards
Selected Journal Publications
- The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma. Bone Marrow Transplantation (2022) 57:1001-1003 2.
- The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft Bone Marrow Transplant. (2021) Sep;56(9):2152-2159
- Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blombery P, Lew TE, Dengler MA, Thompson ER, Lin VS, Chen X, Nguyen T, Panigrahi A, Handunnetti SM, Carney D, Westerman DA, Tam CS, Adams JM, Wei AH, Huang DCS, Seymour JF, Roberts A, Anderson MA. Blood. (2021) Sep 1: blood.2021012775.
- Essential thrombocythaemia and pregnancy- A need for prospective study and a consensus on its management. Burbury K, Panigrahi A. Leuk Res. (2021) Mar;102:106500.
- EMPEROR STUDY- Early Monoclonal Para protein Reduction and Response as predictor of response to treatment in Multiple Myeloma
- Hypercalcemia at diagnosis is an independent predictor of poor survival in DLBCL (3rd author) – Western Health Data.
- An abbreviated schedule of Palifermin before TBI and etoposide conditioning for allogeneic stem cell transplantation is associated with enhanced gut mucositis even in those patients experiencing oral mucositis.
- Azacitadine –Home injection Program – A Single Centre Study Audit at The Prince Charles Hospital, Chermside, Qld
- Hospital audit for Massive Transfusion Protocol, Nambour
- Clinico-aetiologic profile of macrocytic anaemias with special reference to megaloblastic anaemia-Indian Journal of Haematology and Blood Transfusion: Dec 2008 : 24(4):155-165
Professional Memberships
HSANZ (Haematology Society of Australia and New Zealand)
THANZ (Thrombosis and Haemostasis Society of Australia and New Zealand)
ALLG (The Australasian Leukaemia and Lymphoma Group)
ASH (American Society of Haematology)
EHA (European Haematology Association)
ISHBT (Indian Society of Haematology and Blood Transfusion)
